WYAMYCIN S Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Wyamycin S, and when can generic versions of Wyamycin S launch?
Wyamycin S is a drug marketed by Wyeth Ayerst and is included in one NDA.
The generic ingredient in WYAMYCIN S is erythromycin stearate. There is one drug master file entry for this compound. Additional details are available on the erythromycin stearate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for WYAMYCIN S?
- What are the global sales for WYAMYCIN S?
- What is Average Wholesale Price for WYAMYCIN S?
Summary for WYAMYCIN S
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 30 |
| Patent Applications: | 1,091 |
| DailyMed Link: | WYAMYCIN S at DailyMed |
US Patents and Regulatory Information for WYAMYCIN S
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Ayerst | WYAMYCIN S | erythromycin stearate | TABLET;ORAL | 061675-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Wyeth Ayerst | WYAMYCIN S | erythromycin stearate | TABLET;ORAL | 061675-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
